MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopaminergics"

  • 2017 International Congress

    Maximising decrease in Dopaminergic drugs and increase in ON time following Bilateral STN DBS using constant current for Advanced Parkinsons Disease

    S. SANYAL (CALCUTTA (KOLKATA), India)

    Objective: To evaluate the decrease in Dopaminergic drug dosage and increase in ON time following Bilateral STN DBS using constant current for Advanced PD Background:…
  • 2017 International Congress

    Spinal cord stimulation reduces freezing of gait and improves gait in advanced Parkinson’s disease

    O. Samotus, N. Kumar, S. Memar, M. Jog (London, ON, Canada)

    Objective: The primary objective was to investigate the therapeutic effect of spinal cord stimulation (SCS) on gait dysfunction including freezing of gait (FOG) in advanced…
  • 2017 International Congress

    Direct dopaminergic responsiveness of activity performance

    P. Hagell, G.-M. Hariz, B. Sandlund (Kristianstad, Sweden)

    Objective: To assess the direct dopaminergic responsiveness of motor and process aspects of activity performance in people with parkinsonian disorders, and to compare this to…
  • 2016 International Congress

    Duodopa for the treatment of severe restless legs syndrome

    J. Perez-Perez, B. Pascual-Sedano, A. Campolongo, J. Kulisevsky (Barcelona, Spain)

    Objective: To describe the outcome of a patient with restless legs syndrome (RLS) and augmentation phenomena that was treated with Duodopa in continuous infusion. Background:…
  • 2016 International Congress

    Real-life data on the use of levodopa carbidopa intestinal gel in Parkinson’s disease

    J.T. Butler, D. Isaacs, C. Tolleson, R. Pierce, T. Davis (Nashville, TN, USA)

    Objective: To report our institution's initial clinical experience with initiation and management of levodopa carbidopa intestinal gel (LCIG) formulation Duopa®. Background: Carbidopa/levodopa intestinal gel (LCIG)…
  • 2016 International Congress

    Parkinson’s disease patients with onset in right side have a worse cognitive prognosis

    T. Poliakova, I. Zerr, O. Levin (Belgorod, Russia)

    Objective: The our intention was to investigate a dynamics of cognitive decline in patients with different side of onset parkinsonism in view of visual dysfunction…
  • 2016 International Congress

    Illusional perception in Parkinson’s disease

    C. Ding, C. Palmer, J. Hohwy, G. Youssef, B. Paton, N. Tsuchiya, J. Stout, D. Thyagarajan (Clayton, Australia)

    Objective: To investigate (a) whether a susceptibility to illusional perceptions is intrinsic to Parkinson's disease even before the onset of hallucinations or cognitive impairment and…
  • 2016 International Congress

    Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke

    A. Azimov, R. Sadykov, G. Rakhimbaeva, S. Dadajonov, O. Azizova (Tashkent, Uzbekistan)

    Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…
  • 2016 International Congress

    Dopaminergic medication effect on speech in Parkinson’s disease: A kinematic study

    T.E. Tong, M.L. Ng, N. Yan (Hong Kong, Hong Kong)

    Objective: To investigate the effect of levodopa on articulatory movement during Cantonese plosive production in individuals with Parkinson's disease (PD) by comparing kinematic parameters before…
  • 2016 International Congress

    Supplement use in PD is associated with delayed initiation of dopaminergic therapy

    L. Chahine, S. Xie, K. Smith, C. Scordia, R. Purri, C. Linder, J. Duda, N. Dahodwala (Philadelphia, PA, USA)

    Objective: To describe supplement use among early PD patients, and to determine its association with time to initiation of dopamine replacement therapy (DRT). Background: Earlier…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley